Ieq Capital LLC acquired a new stake in shares of Turn Therapeutics Inc. (NASDAQ:TTRX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 227,396 shares of the company's stock, valued at approximately $1,660,000. Ieq Capital LLC owned 0.76% of Turn Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also made changes to their positions in TTRX. Hodges Capital Management Inc. bought a new position in Turn Therapeutics during the 4th quarter valued at about $39,000. LPL Financial LLC bought a new stake in Turn Therapeutics during the fourth quarter worth about $51,000. Tamar Securities LLC bought a new stake in Turn Therapeutics during the fourth quarter worth about $59,000. Composition Wealth LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter worth approximately $63,000. Finally, Geode Capital Management LLC bought a new position in shares of Turn Therapeutics in the fourth quarter valued at approximately $68,000.
Turn Therapeutics Price Performance
Shares of TTRX stock opened at $9.73 on Wednesday. Turn Therapeutics Inc. has a 1 year low of $2.57 and a 1 year high of $26.50. The firm's 50 day moving average is $8.59 and its 200-day moving average is $5.61. The firm has a market capitalization of $289.84 million and a price-to-earnings ratio of -33.55. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83.
Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Sell-side analysts forecast that Turn Therapeutics Inc. will post -0.4 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a "strong-buy" rating in a research report on Monday, July 20th. Zacks Research raised Turn Therapeutics to a "hold" rating in a research note on Tuesday, July 21st. Weiss Ratings cut Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 18th. Finally, Wall Street Zen upgraded Turn Therapeutics to a "hold" rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $8.00.
Check Out Our Latest Analysis on TTRX
Turn Therapeutics Profile
(
Free Report)
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.
Further Reading
Want to see what other hedge funds are holding TTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Turn Therapeutics Inc. (NASDAQ:TTRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Turn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Turn Therapeutics wasn't on the list.
While Turn Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
